Loading...
NPI 1235388679 · Washington, DC · Retina Specialist (Ophthalmology) Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Juanita Bryant is a retina specialist (ophthalmology) physician provider located in Washington, District of Columbia. This profile covers 15 Medicare and 10 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Juanita Bryant |
| Address | 660 Pennsylvania Ave Se |
| City | Washington |
| State | DC |
| ZIP | 20003 |
| Taxonomy | Retina Specialist (Ophthalmology) Physician |
| NPI Enumerated | September 10, 2008 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.9M |
| Medicaid | $239.4K |
Practice profile and service mix align with an outpatient medical retina operation: the provider is a Retina Specialist and the Medicare code mix is dominated by intravitreal therapy and retinal diagnostics (notably J0178, 67028 and 92134), with additional use of intravitreal implant and newer biologic codes such as J7312 and J2777. The presence of high-volume imaging (92134) and extended ophthalmoscopy codes (92202/92201) alongside thousands of injection claims indicates a workflow focused on repeated injections and interval retinal imaging for chronic retinal disease management.
Medicare revenue is highly concentrated: the top three Medicare codes account for 83.9% of this provider's Medicare revenue, led by J0178 (1.2M, 64.0%), followed by 92014 (260.4K, 13.8%) and 67028 (115.4K, 6.1%). This concentration means the practice’s Medicare performance is driven predominantly by anti-VEGF administration and comprehensive ophthalmic evaluations.
Medicaid revenue is similarly concentrated around a small set of services: the top three Medicaid codes account for 74.0% of Medicaid revenue, with 99214 contributing 84.9K (35.5%), J0178 contributing 53.3K (22.3%), and 67028 contributing 38.8K (16.2%). For Medicaid, office E/M visits and intravitreal injections are the primary revenue drivers, reflecting the same chronic-care service line evident in Medicare.
Payer mix is Medicare-dominant in scale: total Medicare revenue is reported as $1.9M while total Medicaid revenue is $239.4K, so Medicare represents the primary revenue stream for this clinician. Medicaid activity is meaningful but materially smaller, indicating the provider operates largely in the Medicare market while maintaining a Medicaid caseload.
National competitive standing is mixed by service line: 92014 is an extreme outlier nationally (2.5K claims; ranks #133 of 35415, 100th percentile), and 92134 is also an extreme outlier (2.4K claims; ranks #691 of 26868, 97th percentile), indicating unusually high national volumes for comprehensive established exams and retinal imaging. By contrast, J0178 (1.8K claims; 1.2M revenue) ranks #663 of 3204 (79th percentile) and is characterized in the data as typical/unremarkable national volume for this injection code, so the provider is exceptional in visit and imaging volume while having a more typical national positioning on aflibercept injection volume.
State-level Medicaid standing shows the provider is a prominent in-state retina resource for certain services: J0178 Medicaid billing ranks #1 of 1 providers in-state (no state peer volume comparison available), 92202 ranks #1 of 7 providers in-state (100th percentile; notably above typical state volume), and 67028 ranks #2 of 8 (86th percentile). These rankings suggest a leading role locally for some diagnostic and injection services under Medicaid.
Operational stability is suggested by tenure: the NPI was enumerated on 2008-09-10 (~18 years ago), indicating a long-established practice footprint. That extended tenure combined with high repeat-service codes (numerous injections and imaging) implies a stable, appointment-driven retina practice with ongoing follow-up care.
Visit-level workload and chronic-care implications are clear from volumes of evaluation codes and repeat procedures: Medicare shows 2.5K claims for 92014 and Medicaid shows 903 claims for 99214, while thousands of injection and imaging claims appear on both payers. This mix—high-volume established-patient E/M visits plus recurring intravitreal injections and retinal imaging—is consistent with management of chronic retinal conditions such as wet AMD and diabetic retinal disease and implies predictable visit cadence and drug-utilization costs for payers.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
15 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 1,750 | $690 | $1.2M |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 2,460 | $110 | $260.4K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 1,120 | $100 | $115.4K |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 3,180 | $30 | $92.2K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,450 | $40 | $88.1K |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 360 | $160 | $56.8K |
| 92202 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 1,880 | $10 | $24.4K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 120 | $130 | $16.1K |
| 92201 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 370 | $20 | $7.8K |
| J7999 | Compounded drug, not otherwise classified | 110 | $70 | $7.2K |
Showing 1–10 of 15
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 15 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
10 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 900 | $90 | $84.9K |
| J0178 | Injection, aflibercept, 1 mg | 30 | $1,840 | $53.3K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 470 | $80 | $38.8K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 1,170 | $30 | $38.4K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 100 | $80 | $7.8K |
| J9035 | Injection, bevacizumab, 10 mg | 110 | $60 | $6.5K |
| 92202 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 410 | $10 | $4.9K |
| 92226 | N/A | 130 | $20 | $2.2K |
| 92201 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 80 | $20 | $1.5K |
| 92235 | The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken… | 20 | $60 | $960 |
How this provider's Medicaid billing volume and revenue compare to other District of Columbia providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. District of Columbia median
10 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 142 | 310 | 750 | $70 | $321.6K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 40 | 50 | 720 | $60 | $80.7K |
| J0178 | Injection, aflibercept, 1 mg | 1 | 10 | 30 | $1,840 | $53.3K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 2 | 10 | 250 | $120 | $35.2K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 8 | 20 | 1,100 | $20 | $25.3K |
| 92201 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 3 | 10 | 80 | $20 | $4.3K |
| J9035 | Injection, bevacizumab, 10 mg | 2 | 10 | 60 | $40 | $3K |
| 92226 | N/A | 2 | 10 | 90 | $10 | $1.3K |
| 92202 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 1 | 10 | 40 | $10 | $1.1K |
| 92235 | The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken… | 1 | 10 | 20 | $60 | $960 |
Other providers in the same ZIP code as Juanita Bryant, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Universal Home Healthcare Inc. | DC | Home Health Agency | $0 | $69.8M |
| Community Connections Inc | DC | Mental Health Clinic/Center (Including Community Mental Health Center) | $0 | $69.4M |
| Iya Homes And Community Solutions, LLC | DC | Community/Behavioral Health Agency | $0 | $11.3M |
| Psi Services 111 Inc. | DC | Developmentally Disabled Services Day Training Agency | $0 | $5.4M |
| Husband Therapeutics | DC | Home Health Agency | $0 | $2.7M |
| Accent On Health, LLC | DC | Internal Medicine Physician | $0 | $1.3M |
| Grubbs Pharmacy Of Dc Inc | DC | Community/Retail Pharmacy | $106.5K | $935.3K |
| Alfred Burris | DC | Cardiovascular Disease Physician | $469.2K | $356.3K |
| Christopher Burris | DC | Ophthalmology Physician | $127.7K | $642.6K |
| Phase Ll Academy | DC | Specialist | $0 | $751.8K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.